{"filing":{"accession_number":"0001104659-26-075849","cik":"0001815903","ticker":"PTPI","company_name":"Petros Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"tm2618334d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/tm2618334d1_8k.htm"},"events":[{"id":11987,"run_id":10548,"accession_number":"0001104659-26-075849","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both a departure (Mitchell Arnold's separation as VP of Finance and Principal Accounting Officer) and an appointment (Robert Weinstein's appointment as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately). While both events occur on the same date, the appointment of Weinstein—a seasoned CFO with 30+ years of experience in healthcare finance—represents the principal forward-looking action and is emphasized in the disclosure structure. The appointment fills a critical financial leadership role and is material to investors assessing the company's financial oversight.","company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8716,"accession_number":"0001104659-26-075849","item_number":"5.02","item_title":"Departure of Directors","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a departure (Mitchell Arnold's separation as VP of Finance and Principal Accounting Officer) and an appointment (Robert Weinstein's appointment as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately). While both events occur on the same date, the appointment of Weinstein—a seasoned CFO with 30+ years of experience in healthcare finance—represents the principal forward-looking action and is emphasized in the disclosure structure. The appointment fills a critical financial leadership role and is material to investors assessing the company's financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:16:06.149105+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8716,"accession_number":"0001104659-26-075849","item_number":"5.02","item_title":"Departure of Directors","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a departure (Mitchell Arnold's separation as VP of Finance and Principal Accounting Officer) and an appointment (Robert Weinstein's appointment as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately). While both events occur on the same date, the appointment of Weinstein—a seasoned CFO with 30+ years of experience in healthcare finance—represents the principal forward-looking action and is emphasized in the disclosure structure. The appointment fills a critical financial leadership role and is material to investors assessing the company's financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:16:06.149105+00:00","company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","filing_date":"2026-06-18"}]}